Nutra Pharma releases pain drug Nyloxin Rx for US distribution; seeking partners

Florida, USA-based biotechnology firm Nutra Pharma, which is developing treatments for adrenomyeloneuropathy, HIV and multiple sclerosis, says that it has completed manufacturing the first batch of its prescription pain reliever, Nyloxin Rx, and has successfully released it for initial marketing-related distribution within the USA.

"We are pleased to be announcing the rollout of the company's first prescription drug, Nyloxin Rx," commented Rik Deitsch, chairman and chief executive of "As we move forward with the launch of Nyloxin Rx, we continue to seek partnerships with established US and international distributors to assist us with ongoing marketing to physician offices, hospitals and medical clinics," he added.

Nyloxin Rx is a prescription pain reliever clinically proven to treat Stage 3 (severe) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one's ability to fully function.